Future Outlook of the Stelara (Ustekinumab) Market: Growth, Trends, and Emerging Opportunities Explored
Enjoy a flat 15% OFF on all 2025 Global Market Reports until March 31st! Use code FY25SAVE to save big—don’t miss out!
How has the stelara (ustekinumab) market size evolved in recent years?
In recent times, the market size for stelara (ustekinumab) has experienced significant growth. Its projected growth will see an escalation from a monetary value of $11,177.34 million in 2024 to $11,850.79 million in 2025, representing a compound annual growth rate (CAGR) of 6.0%. Factors such as an increase in healthcare expenditure, the development of special medicine distribution channels, expansion of clinical trial programs, investment in R&D, and broader access to treatment through telemedicine have contributed to the historic growth.
What are the predictions for the stelara (ustekinumab) market size in the coming years?
The market size for stelara (ustekinumab) is anticipated to experience significant growth in the coming years, reaching a value of $14,768.48 million in 2029 with a compound annual growth rate (CAGR) of 5.7%. This predicted growth during the forecast period is due to several factors including the increasing use of stelara for various indications, a rise in cases of autoimmune diseases, its superior efficacy in refractory situations compared to other options, increased awareness among patients and medical professionals, and an amplified focus on personalized medicine. Main trends throughout the forecast period involve the incorporation of biologic therapies, the progression of advanced drug delivery systems, data-centric healthcare systems, collaborations and licenses among pharma firms, and improvements in biologics production technologies.
Get your stelara (ustekinumab) market report here!
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-
What key factors are fueling the growth of the stelara (ustekinumab) market?
The increase in the number of individuals battling psoriasis, a chronic autoimmune condition that causes rapid skin cell turnover and results in red, flaky skin patches, is likely to drive the expansion of the stelara (ustekinumab) market. Several factors, including enhanced diagnostic techniques, environmental factors, genetic susceptibility, and an aging demographic, contribute to this growth of psoriasis cases. By effectively inhibiting interleukin-12 and interleukin-23, stelara (ustekinumab) helps psoriasis patients minimize inflammation and plaque formation, leading to better skin health, longer relief from symptoms, and ultimately an improved quality of life. For example, a report by the National Library of Medicine, a U.S.-based medical library, highlighted that in 2024 the incidence of psoriasis elevated to 0.221%, with a total of 6,930 PsA incidents reported out of a population of 3,133,500 in 2022. Consequently, the growing number of psoriasis patients is anticipated to steer the growth of the stelara (ustekinumab) market.
How is the global stelara (ustekinumab) market divided into key segments?
The stelara (ustekinumab)market covered in this report is segmented –
1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Pediatric; Adult; Geriatric
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp
Who are the key firms paving the way for growth in the stelara (ustekinumab) market?
Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson
Which trends are expected to transform the stelara (ustekinumab) market?
The significant trend in the Stelara (Ustekinumab) market involves the creation of innovative products like Stelara biosimilars to provide affordable therapeutic options to patients with chronic inflammatory conditions. Stelara biosimilars, which are biologically similar drugs designed to mimic the therapeutic effects of Stelara, target IL-12 and IL-23 to treat autoimmune diseases like psoriasis and psoriatic arthritis. As an example, Accord BioPharma Inc., an American biopharmaceutical firm, announced in October 2024 that the U.S Food and Drug Administration (FDA) had granted approval for IMULDOSA (ustekinumab-srlf), a Stelara biosimilar. Notably, IMULDOSA’s broad therapeutic indications include treatment for adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. Uniquely, it also extends to pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis. This wide-ranging applicability situates IMULDOSA as a useful resource for handling multiple immune-mediated inflammatory diseases.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935
What regions are contributing significantly to the growth of the stelara (ustekinumab) market?
North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Psoriasis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Radiosurgery And Radiotherapy Robotics Global Market Report 2025
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
